Search research articles
Contact Us
Filters
Showing results (71-80 of 101) with videos related to
Page
of 11
Sort By:
Cancer
|
September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
Darren R Feldman, Yasser Ged, Chung-Han Lee, et al.
European Urology
|
February 13, 2021
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]
Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology
|
February 20, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
Maria I Carlo, Kyrollis Attalla, Yousef Mazaheri, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
European Urology Focus
|
March 15, 2022
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
Angela Yoo, Cerise Tang, Mark Zucker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Martin H Voss, Ana M Molina, Ying-Bei Chen, et al.
European Urology Oncology
|
March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma
Ritesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Cancer Cell
|
January 15, 2016
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
A Ari Hakimi, Ed Reznik, Chung-Han Lee, et al.
Cell Metabolism
|
July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
Cerise Tang, Amy X Xie, Eric Minwei Liu, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 101) with videos related to
Sort By:
Page
of 11
Cancer
|
September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
Darren R Feldman, Yasser Ged, Chung-Han Lee, et al.
European Urology
|
February 13, 2021
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15]
Min Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology
|
February 20, 2022
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
Maria I Carlo, Kyrollis Attalla, Yousef Mazaheri, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2022
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates
Chung-Han Lee, Martin H Voss, Maria Isabel Carlo, et al.
European Urology Focus
|
March 15, 2022
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
Angela Yoo, Cerise Tang, Mark Zucker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2016
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Martin H Voss, Ana M Molina, Ying-Bei Chen, et al.
European Urology Oncology
|
March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma
Ritesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Cancer Cell
|
January 15, 2016
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma
A Ari Hakimi, Ed Reznik, Chung-Han Lee, et al.
Cell Metabolism
|
July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
Cerise Tang, Amy X Xie, Eric Minwei Liu, et al.
Page
of 11